Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | ACACB | O00763 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005166 | 0.88 | GAA (0.50) | CCR5ACACBHTR2AHTR2CGHSR | |
| SCHEMBL12004655 | 0.84 | HTR2A (0.50) | CCR5ACACBHTR2AHTR2CMAPT | |
| SCHEMBL12005036 | 0.82 | CCR5 (0.50) | CCR5HTR2AHTR2CLMNAGHSR | |
| SCHEMBL12004803 | 0.80 | NPY5R (0.47) | CCR5HTR2AHTR2CMAPTHTT | |
| SCHEMBL12004406 | 0.80 | HTR2A (0.48) | CCR5HTR2AHTR2CMAPTGHSR | |
| SCHEMBL12006140 | 0.79 | HTT (0.56) | CCR5HTR2AHTR2CMAPTGHSR | |
| SCHEMBL18686204 | 0.78 | GHSR (0.54) | HTR2AGHSRHTT | |
| SCHEMBL12004926 | 0.77 | GHSR (0.61) | CCR5HTR2AHTR2CGHSRHTT | |
| SCHEMBL12004560 | 0.77 | GHSR (0.51) | CCR5HTR2AHTR2CMAPTGHSR | |
| SCHEMBL17207682 | 0.76 | TSHR (0.46) | CCR5HTR2ALMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | CCR5 3085/4885ACACB 2262/4885HTR2A 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.